Immune cell therapy shows promise in early trial for advanced cancers
NCT ID NCT04050709
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 25 times
Summary
This early-phase study tested a new immune cell treatment called PD-L1 t-haNK in 16 adults with advanced solid tumors that had spread or could not be removed by surgery. The main goals were to check the treatment's safety, find the best dose, and see if it could shrink tumors. The study is complete, and results will help guide future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chan Soon-Shiong Institute for Medicine
El Segundo, California, 90245, United States
Conditions
Explore the condition pages connected to this study.